MedTrace Logo

Quetiapine (Seroquel) Maintenance Treatment in Early Onset Bipolar Spectrum Disorders

NCT00252226 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2008-06-04

No results posted yet for this study

Summary

This is a single center, open prospective study to evaluate the effectiveness of quetiapine monotherapy in the maintenance treatment of adolescent patients with a bipolar spectrum disorder (bipolar I and bipolar II disorders, cyclothymia, and bipolar disorder not otherwise specified \[bipolar NOS\]) for a minimum of 48 weeks. Patients will be screened (enrolment phase) either when already stabilized or during an acute episode of mania/hypomania or depression.

Conditions

Interventions

DRUG

Quetiapine

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Mood Disorders Center of Ottawa

    lead OTHER

Principal Investigators

  • Paul Grof, M.D. · Mood Disorders Center of Ottawa

  • Anne Duffy, M.D. · Mood Disorders Center of Ottawa

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
12 Years
Max Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-06-30
Primary Completion
2007-12-31
Completion
2007-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00252226 on ClinicalTrials.gov